About GlycoVaxyn
GlycoVaxyn is a Healthcare company based in Schlieren (Switzerland) founded in 2004 by Michael Wacker, and was acquired by GSK in February 2015. Bioconjugate vaccines for bacterial infections are developed using proprietary technology. GlycoVaxyn has raised $32.12 million across 4 funding rounds from investors including Edmond de Rothschild, GSK and Index Ventures. Its chief executive, as recorded, is Philippe Dro. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.
Company details
Founded in 2004 and based in Schlieren, Switzerland, bioconjugate vaccines are developed by the company to address bacterial infections. A proprietary glycoprotein technology is employed to produce these vaccines in bacterial cells, bypassing chemical conjugation methods. Operations focus on a portfolio of prophylactic and therapeutic options for common severe infections, within the biotechnology sector targeting vaccine innovation.
- Headquarters Schlieren, Switzerland
- Founders Michael Wacker
- Stage Acquired
- SectorsHealthcare
- Website glycovaxyn.com
- Social LinkedIn
- Acquired by GSK (Feb 2015)
- Total Equity Funding$32.12M (USD)
in 4 rounds
- Latest Funding Round$22M (USD), Series B
Mar 2009
- InvestorsEdmond de Rothschild
& 3 more
- Acquired byGSK
(Feb 2015)
Funding Insights of GlycoVaxyn
GlycoVaxyn has successfully raised a total of $32.12M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $22 million completed in March 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.12M
- Total Rounds 4
- Last Round Series B β $22M
- First Round $817,000
(Jul 2006)
- Investors Count 3
All 4 funding rounds of GlycoVaxyn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2009 | $22M | Series B | β | Edmond de Rothschild | |
| Feb 2009 | Series A | β | β | β | |
| Jul 2007 | $9.3M | Series A | β | Index Ventures, Sofinnova Partners | β |
| Jul 2006 | $817,000 | Seed | β | Index Ventures, Sofinnova Partners | β |
4 investors in total: 4 institutional.
Investors in GlycoVaxyn
GlycoVaxyn has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Edmond de Rothschild, GSK and Index Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology startups and entrepreneurs. | indexventures.com | |||
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors | 1953 | edmond-de-rothschild.com | Paris, France | |
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom |
Investor details for GlycoVaxyn
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GlycoVaxyn
2 people are tracked at GlycoVaxyn (2 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Wacker | Co-Founder | Leadership |
Philippe Dro | CEO | Leadership |
Complete people profiles for GlycoVaxyn
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GlycoVaxyn
4 dated milestones of GlycoVaxyn across 11 years, from founding to its latest funding, stage changes and deals.
- Founded GlycoVaxyn is founded.
- Funding First funding round of $817K.
- Funding Latest funding round, Series B, of $22.0M.
- Exit Acquired by GSK.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glycovaxyn
Complete news archive for GlycoVaxyn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GlycoVaxyn
GlycoVaxyn was founded in 2004 and raised its 1st funding round 2 years after it was founded.
GlycoVaxyn is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Philippe Dro is the CEO of GlycoVaxyn, as recorded in our data.
GlycoVaxyn is a funded company, having raised a total of $32.12M across 4 funding rounds to date. The company's 1st funding round was a Seed of $817K, raised on Jul 2006.
Founded in 2004 and based in Schlieren, Switzerland, bioconjugate vaccines are developed by the company to address bacterial infections. A proprietary glycoprotein technology is employed to produce these vaccines in bacterial cells, bypassing chemical conjugation methods. Operations focus on a portfolio of prophylactic and therapeutic options for common severe infections, within the biotechnology sector targeting vaccine innovation.
GlycoVaxyn has 4 investors. Key investors include Edmond de Rothschild, GSK, Index Ventures, and Sofinnova Partners.
Yes. GlycoVaxyn was acquired by GSK in February 2015.

